English
Use of metformin in patients who require intravascular administration of a contrast agent
Abstract
Metformin is a drug that has been widely used around the world for many years. Due to its properties, metformin is used in the treatment of carbohydrate disorders (in type 2 diabetes, prediabetes) and in insulin resistance syndromes (including polycystic ovary syndrome).
Many patients using metformin, due to complications of carbohydrate metabolism disorders, including cardiovascular complications or other accompanying diseases, require cardiological or radiological diagnostics related to the administration of a contrast agent.
The aim of this study is to summarize the recommendations regarding the use of metformin before procedures involving the use of contrast agents and to share our own experience in this area, based on observations of a large group of patients with cardiological diseases hospitalized at the Silesian Centre for Heart Diseases in Zabrze.
Keywords: metformincontrast agents
References
- GLUCOPHAGE. Charakterystyka Produktu Leczniczego. https://leki.urpl.gov.pl/files/43_Glucophage_500_mg_tabl_powl_500mg.pdf.
- Christensen MMH, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011; 21(12): 837–850.
- Gong Li, Goswami S, Giacomini KM, et al. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012; 22(11): 820–827.
- Wróbel MP, Marek B, Kajdaniuk D, et al. Metformin — a new old drug. Endokrynol Pol. 2017; 68(4): 482–496.
- van der Molen A, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR (European Society of Urogenital Radiology) Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7): 2856–2869.
- Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2022. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetol Klin. 2022; 2(Supl. A): 1–133.
- Navaneethan SD, Zoungas S, Caramori ML, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4S): S1–S115.
- Shams E, Mayrovitz HN. Contrast-Induced Nephropathy: A Review of Mechanisms and Risks. Cureus. 2021; 13(5): e14842.
- Goergen SK, Rumbold G, Compton G, et al. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010; 254(1): 261–269.
- Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committe. Eur Radiol. 1999; 9: 738–740.
- Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312(24): 2668–2675.
- Richy FF, Sabidó-Espin M, Guedes S, et al. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014; 37(8): 2291–2295.
- Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003; 163(21): 2594–2602.
- van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury — Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7): 2845–2855.
- ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media. https://www.acr.org/-/media/ACR/files/clinical-resources/contrast_media.pdf.
- Food and Drug Administration (FDA). FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm (15 December 2017).
- Van der Molen AJ, Geenen RWF, Dekkers HM et al for the Radiological Society of the Netherlands (RSTN). Guideline safe use of contrast media, part 1. Vught, RSTN: 2017.
